Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Mitesh J. Borad(Jacksonville College), John D. Carpten(City of Hope)
Cited by 341
Related Papers
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Moving AHEAD with an international human epigenome project
|Nature|2008|185
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
|Annals of Oncology|2022|138
Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers
|JCO Precision Oncology|2019|86